Active substance
Results for the substance velmanase alfa
1 result
About this active substance
Velmanase alfa is a medication used for the treatment of Fabry disease, a rare genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A. This deficiency leads to the accumulation of globotriaosylceramide (Gb3) in cells, affecting the function of organs such as the kidneys, heart, and nervous system. Velmanase alfa is a recombinant form of the alpha-galactosidase A enzyme, which helps break down and remove Gb3 from cells.
The medication is administered intravenously, usually once a week, and treatment requires regular monitoring to assess efficacy and safety.
Common side effects include injection site reactions, headaches, nausea, and fever. In rare cases, severe adverse reactions such as allergic reactions or kidney function impairment may occur.
Velmanase alfa represents an important therapeutic option for patients with Fabry disease, helping to reduce Gb3 accumulation and improve their quality of life.
The medication is administered intravenously, usually once a week, and treatment requires regular monitoring to assess efficacy and safety.
Common side effects include injection site reactions, headaches, nausea, and fever. In rare cases, severe adverse reactions such as allergic reactions or kidney function impairment may occur.
Velmanase alfa represents an important therapeutic option for patients with Fabry disease, helping to reduce Gb3 accumulation and improve their quality of life.